Efficacy and safety of sacral nerve root magnetic stimulation combined with solifenacin in female patients with overactive bladder
Yan Dong · American Journal of Translational Research · 2025
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
American Journal of Translational Research · e-Century Publishing Corporation · article · 2025
Abstract
Objective: This study aimed to assess the efficacy and safety of sacral nerve root magnetic stimulation (SNRMS) combined with solifenacin in female patients with overactive bladder (OAB) symptoms.Methods: A total of 183 female patients with OAB symptoms were prospectively randomized into 2 groups.Ninety-two patients in the combination group accepted SNRMS and solifenacin therapy and 91 patients serving as control accepted only solifenacin therapy.The lower urinary tract symptoms, OAB questionnaire (OAB-q) health-related quality of life (HRQoL), symptom bother score, and overactive bladder syndrome score (OABSS) were compared between the two groups at the end of the second, fourth, and eighth weeks.Results: The incidence of lower urinary tract symptoms, including urgency, frequent urination, and incontinence episodes, was significantly lower in the fourth and eighth weeks in patients of the combination treatment group than those in the solifenacin group (P < 0.05).The incidence of drugrelated adverse events in the two groups was similar, with no statistically significant difference (P > 0.05).The OAB-q HRQoL score in the combination group was significantly higher than that in the solifenacin group between the fourth and eighth weeks (P < 0.05).Meanwhile, the OAB-q symptom bother score and OABSS were both lower in the combination group than those in the solifenacin group from the fourth to eighth weeks (P < 0.05).Conclusions: The combination therapy of SNRMS and solifenacin demonstrated significant improvements over solifenacin monotherapy in reducing OAB symptoms in female patients, providing a higher QoL without increasing bothersome adverse effects.
Open the resolved locator · 10.62347/ehtt9544
Metadata licence: OpenAlex metadata (CC0)